Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Journal of Cannabis Research|January 16, 2026
The differential effects of CBD and CBDA on viability and mRNA expression in colorectal cancer cellsChristine Heinzle, Kathrin Geiger, Reinhard Ertl, et al.
Atherosclerosis|April 22, 2009
Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosisAxel Muendlein, Simone Geller-Rhomberg, Christoph H Saely, et al.
European Journal of Clinical Investigation|November 3, 2025
Angiopoietin-like protein 2 and mortality in patients with heart failure-Results from an observational studyEva Maria Brandtner, Andreas Leiherer, Barbara Larcher, et al.
Plos One|March 23, 2011
Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosisAxel Muendlein, Christoph H Saely, Simone Geller-Rhomberg, et al.
Atherosclerosis|August 9, 2015
Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patientsAxel Muendlein, Andreas Leiherer, Christoph H Saely, et al.
Plos One|October 8, 2009
CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patientsAriane Biebl, Axel Muendlein, Zhyrgal Kazakbaeva, et al.
Oncology Research and Treatment|January 29, 2026
Clinical Prognostic Significance of LRG1 in Metastatic Breast CancerAxel Muendlein, Eva Maria Brandtner, Christine Heinzle, et al.
Plos One|November 1, 2011
Identification of hypoxia-induced genes in human SGBS adipocytes by microarray analysisKathrin Geiger, Andreas Leiherer, Axel Muendlein, et al.
Breast Cancer Research and Treatment|May 23, 2019
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancerThomas Decker, Norbert Marschner, Axel Muendlein, et al.
International Journal of Cardiology|August 9, 2022
Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery diseaseAxel Muendlein, Christine Heinzle, Andreas Leiherer, et al.
Pageof 9